Association of CD40 SNPs with Moyamoya in a Chinese children population

References

• Suzuki J, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969;20:288–99.
   PubMed Web of Science ®Google Scholar
• Bersana A, Guey S, Bedini G. European Moyamoya Disease Initiative: research progresses in understanding the pathophysiology of Moyamoya disease. Cerebrovasc Dis 2016;41:105–18.
   PubMed Web of Science ®Google Scholar
• Achrol AS, Guzman R, Lee M, Steinberg GK. Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus 2009;26:E4. doi:10.3171/2009.1.FOCUS08302
   PubMed Web of Science ®Google Scholar
• Kim SJ, Heo KG, Shin HY. Association of thyroid autoantibodies with moyamoya type cerebrovascular disease: a prospective study. Stroke 2010;41:173–6.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang ZS, Dong ZN, et al. Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease: a case-control study. Stroke 2011;42:1138–9.
   PubMed Web of Science ®Google Scholar
• El Ramahi KM, Al Rayes HM. Systemic lupus erythematosus associated with Moyamoya syndrome. Lupus 2000;9:632–6.
   PubMed Web of Science ®Google Scholar
• Watanabe C, Oishi T, Yamamoto T, et al. Chorea and Broca aphasia induced by diabetic ketoacidosis in a type 1 diabetic patient diagnosed as moyamoya disease. Diabetes Res Clin Pract 2005;67:180–5.
   PubMed Web of Science ®Google Scholar
• Chen JB, Liu Y, Zhou LX, Sun H, He M, You C. Increased prevalence of autoimmune disease in patients with unilateral compared with bilateral Moyamoya disease. J Neurosurg 2016;124:1215–20.
   PubMed Web of Science ®Google Scholar
• Bower RS, Mallory GW, Nwojo M, Kudva YC, Flemming KD, Meyer FB. Moyamoya disease in a primarily White, Midwestern US Population: increased prevalence of antoimmune disease. Stroke 2013;44:1997–9.
   PubMed Web of Science ®Google Scholar
• Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003;2:119–25.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Arakawa Y, Suqino T, et al. Three cases of Moyamoya disease with a history of Kawasaki disease. No Shinkei Geka 2015;43:1005–10.
   PubMedGoogle Scholar
• Liang CD, Kuo HC, Yang KD, Wang CL, Ko SF. Coronary artery fistula associated with Kawasaki disease. Am Heart J 2009;157:584–8.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Kuo HC, Chang JS, et al. Replication and meta-analysis of GWAS identified susceptibility loci in Kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility. PLos One 2013;8:e72037. doi:10.1371/journal.pone.0072037
   PubMed Web of Science ®Google Scholar
• Peng Q, Chen CH, Wu Q, Yang Y. Meta-analyses of the associations of genome-wide association study- linked gene loci with Kawasaki disease. Zhong Hua Er Ke Za Zhi 2013;51:571–7.
   PubMedGoogle Scholar
• Kuo HC, Chao MC, Hsu YW, et al. CD40 Gene polymorphisms associated with susceptibility and coronary artery lesions of Kawasaki disease in the Taiwanese population. Scientific World Journal 2012;2012:1. doi:10.1100/2012/520865
   Google Scholar
• Tsai FJ, Lee YC, Chang JS, et al. Identification of novel susceptibility Loci for Kawasaki disease in a Han Chinese population by a genome-wide association study. PLoS One 2011;6:e16853. doi:10.1371/journal.pone.0016853
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Tominaga T, Miyamoto S, et al. Guidelines for diagnosis and treatment of Moyamoya disease (Spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 2012;52:245–66.
   PubMedGoogle Scholar
• Park YS, Jeon YJ, Kim HS, et al. The GC + CC genotype at position -418 in TIMP-2 promoter and the -1575GA/-1306CC genotype in MMP-2 is genetic predisposing factors for prevalence of moyamoya disease . BMC Neurol 2014;14:180. doi:10.1186/s12883-014-0180-5
   PubMed Web of Science ®Google Scholar
• Koizumi A, Kobayashi H, Hitomi T, Harada KH, Habu T, Youssefian S. A new horizon of Moyamoya disease and associated health risks explored through RNF213. Environ Health Prev Med 2016;21:55–70.
   PubMed Web of Science ®Google Scholar
• Roder C, Peters V, Kasuya H, et al. Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir (Wien) 2010;152:2153–60.
   PubMed Web of Science ®Google Scholar
• Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003;90:377–84.
   PubMed Web of Science ®Google Scholar
• Senhaji N, Kojok K, Darif Y, Fadaina C, Zaid Y. The contribution of CD40/CD40L axis in inflammatory bowel disease: an update. Front Immunol 2015;16:529. doi:10.3389/fimmu.2015.00529
   Google Scholar
• Chandel HS, Pandey SP, Roy S, Doyen N, Saha B. TLR-CD40 cross-talk in anti-leishmanial immune response. Front Immunol 2014;16:220. doi:10.3389/fimmu.2014.00220
   Google Scholar
• Pinelli DF, Ford ML. Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. Immunotherapy 2015;7:399–410. doi:10.2217/imt.15.1
   PubMed Web of Science ®Google Scholar
• Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med 2011;43:331–40.
   PubMed Web of Science ®Google Scholar
• Vowinkel T, Wood KC, Stokes KY, Russell J, Krieglstein CF, Granger DN. Differential expression and regulation of murine CD40 in regional vascular beds. Am. J. Physiol. Heart Circ. Physiol 2006;290:H631–9.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Blair P, Freedman JE. CD40-40L signaling in vascular inflammation. J Biol Chem 2007;282:18307–17.
   PubMed Web of Science ®Google Scholar
• Mukundan L, Milhorn DM, Matta B, Suttles J. CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated, MAPK-dependent pathway. Cell Signal 2004;16:375–84.
   PubMed Web of Science ®Google Scholar
• Reid AJ, Bhattacharjee MB, Reqalado ES, et al. Diffuse and uncontrolled vascular smooth muscle cell proliferation in rapidly progressing pediatric Moyamoya disease. J Neurosurg Pediatr 2010;6:244–9.
   PubMed Web of Science ®Google Scholar
• Hervé D, Philippi A, Belbouab R, et al. Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to Moyamoya and achalasia. Am J Hum Genet 2014;94:385–94.
   PubMed Web of Science ®Google Scholar
• Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schönbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002;277:25032–9.
   PubMed Web of Science ®Google Scholar
• Smith ER, Scott RM. Moyamoya: epidemiology, presentation, and diagnosis. Neurosurg Clin N Am 2010;21:543–51. doi:10.1016/j.nec.2010.03.007
   PubMed Web of Science ®Google Scholar
• Hosoda Y, Ikeda E. Pathology of spontaneous occlusion of the circle of Willis (cerebrovascular Moyamoya disease). Neuropathology 1999;19:137–8.
   PubMed Web of Science ®Google Scholar
• Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002;4:105–11.
   PubMed Web of Science ®Google Scholar
• Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 1993;24:1960–7.
   PubMed Web of Science ®Google Scholar
• Young AM, Karri SK, Ogilvy CS, Zhao N. Is there a role for treating inflammation in moyamoya disease? A review of histopathology, genetics, and signaling cascades. Front Neurol 2013;4:105. doi:10.3389/fneur.2013.00105
   PubMed Web of Science ®Google Scholar
• Luheshi N, Davies G, Legg J. Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists. Oncoimmunology 2014;3:e27615
   PubMed Web of Science ®Google Scholar
• Yip H-K, Chang L-T, Sun C-K, et al. Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol 2006;97:192–4.
   PubMed Web of Science ®Google Scholar
• Roder C, Peters V, Kasuya H, et al. Common genetic polymorphisms in Moyamoya and atherosclerotic disease in Europeans. Childs Nerv Syst 2011;27:245–52.
   PubMed Web of Science ®Google Scholar